-
EP1458411
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP1458411
| EP1458411 - ANTI-RANK LIGAND MONOCLONAL ANTIBODIES USEFUL IN TREATMENT OF RANK LIGAND MEDIATED DISORDERS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 28.07.2006 Database last updated on 15.11.2024 | Most recent event Tooltip | 28.07.2006 | Application deemed to be withdrawn | published on 30.08.2006 [2006/35] | Applicant(s) | For all designated states SMITHKLINE BEECHAM CORPORATION One Franklin Plaza P.O. Box 7929 Philadelphia Pennsylvania 19103 / US | For all designated states SMITHKLINE BEECHAM PLC New Horizons Court Brentford Middlesex TW8 9EP / GB | [N/P] |
| Former [2004/39] | For all designated states SMITHKLINE BEECHAM CORPORATION One Franklin Plaza P.O. Box 7929 Philadelphia Pennsylvania 19103 / US | ||
| For all designated states SMITHKLINE BEECHAM PLC New Horizons Court Brentford, Middlesex TW8 9EP / GB | Inventor(s) | 01 /
SWEET, Raymond, W. 108 Edgehill Road Bala-Cynwyd, PA 19004 / US | 02 /
TORNETTA, Mark, A. 200 Great Valley Parkway Malvern, PA 19355 / US | 03 /
TRUNEH, Alemseged 709 Swedeland Road King of Prussia, PA / US | 04 /
WATTAM, Trevor A. New Frontiers Science Park South, Third Avenue Harlow, Essex CM19 5AW / GB | [2004/39] | Representative(s) | Giddings, Peter John, et al GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road Brentford, Middlesex TW8 9GS / GB | [N/P] |
| Former [2004/39] | Giddings, Peter John, Dr., et al GlaxoSmithKline Corporate Intellectual Property (CN9.25.1) 980 Great West Road Brentford, Middlesex TW8 9GS / GB | Application number, filing date | 01968064.4 | 21.08.2001 | [2004/39] | WO2001US26161 | Priority number, date | US20000226524P | 21.08.2000 Original published format: US 226524 P | US20000230639P | 07.09.2000 Original published format: US 230639 P | [2004/39] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO0215846 | Date: | 28.02.2002 | Language: | EN | [2002/09] | Type: | A2 Application without search report | No.: | EP1458411 | Date: | 22.09.2004 | Language: | EN | The application published by WIPO in one of the EPO official languages on 28.02.2002 takes the place of the publication of the European patent application. | [2004/39] | Search report(s) | International search report - published on: | US | 01.07.2004 | (Supplementary) European search report - dispatched on: | EP | 12.07.2004 | Classification | IPC: | A61K39/395, C07K16/28, C12N5/18 | [2004/39] | CPC: |
C07K16/2875 (EP,US);
A61P1/04 (EP);
A61P17/06 (EP);
A61P19/02 (EP);
A61P19/08 (EP);
A61P19/10 (EP);
A61P25/28 (EP);
A61P29/00 (EP);
A61P3/10 (EP);
A61P43/00 (EP);
A61K2039/505 (EP,US);
C07K2317/56 (EP,US);
C07K2317/565 (EP,US)
(-)
| Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2004/39] | Title | German: | ANTI-RANK LIGANDEN MONOKLONALE ANTIKÖRPER NÜTZLICH ZUR BEHANDLUNG VON RANK LIGANDEN VERMITTELTEN STÖRUNGEN | [2004/39] | English: | ANTI-RANK LIGAND MONOCLONAL ANTIBODIES USEFUL IN TREATMENT OF RANK LIGAND MEDIATED DISORDERS | [2004/39] | French: | ANTICORPS MONOCLONAUX LIGANDS ANTI-RANK CONVENANT AU TRAITEMENT DE TROUBLES LIES AUX LIGANDS DE RANK | [2004/39] | Entry into regional phase | 21.02.2003 | National basic fee paid | 21.02.2003 | Search fee paid | 21.02.2003 | Designation fee(s) paid | 21.02.2003 | Examination fee paid | Examination procedure | 05.02.2002 | Request for preliminary examination filed International Preliminary Examining Authority: US | 21.02.2003 | Examination requested [2004/39] | 01.03.2006 | Application deemed to be withdrawn, date of legal effect [2006/35] | 06.04.2006 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2006/35] | 22.05.2006 | Despatch of a communication from the examining division (Time limit: M04) | Fees paid | Renewal fee | 06.08.2003 | Renewal fee patent year 03 | 06.08.2004 | Renewal fee patent year 04 | Penalty fee | Additional fee for renewal fee | 31.08.2005 | 05 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]WO9525167 (MERCK PATENT GMBH [DE], et al) [X] 5,7,9,10 * page 65; claim 4 *; | [X]EP0921395 (PFIZER PROD INC [US]) [X] 5,7,9,10* page 45; claim 10 *; | [X]WO9929865 (UNIV ROCKEFELLER [US]) [X] 1,13 * abstract * * page 5, lines 3-11 * * page 9, lines 6-27 * * page 11, line 15 - page 12, line 15 * * page 32, line 3 - page 33, line 7 * * page 51, line 19 - page 54, line 17 *; | [X]WO0015807 (M & E BIOTECH A S [DK], et al) [X] 1,13 * abstract * * page 1, lines 3-18 * * page 7, lines 9-25 * * page 9, lines 11-15 * * page 40, line 25 - page 41, line 7 *; | [X] - MENAA C ET AL, "Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone.", THE JOURNAL OF CLINICAL INVESTIGATION. JUN 2000, (200006), vol. 105, no. 12, ISSN 0021-9738, pages 1833 - 1838, XP002278692 [X] 1,13 * abstract * * page 1834, column 2, paragraph 3 * DOI: http://dx.doi.org/10.1172/JCI9133 | [X] - TSUKII KATSUYOSHI ET AL, "Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, &, (19980519), vol. 246, no. 2, ISSN 0006-291X, pages 337 - 341, XP002278693 [X] 1,13 * abstract * * page 338, column 1, paragraph 4 * DOI: http://dx.doi.org/10.1006/bbrc.1998.8610 | [X] - NAGAI MASAZUMI ET AL, "Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, &, (20000316), vol. 269, no. 2, ISSN 0006-291X, pages 532 - 536, XP002278694 [X] 1,13 * abstract * * page 535, column 2, paragraph 2 * DOI: http://dx.doi.org/10.1006/bbrc.2000.2314 | International search | [X]US5530101 (QUEEN CARY L [US], et al); | [X]US5840299 (BENDIG MARY M [GB], et al); | [Y]US6017729 (ANDERSON DIRK M [US]); | [Y] - YASUDA ET AL., "Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL", PROC. NATL. ACAD. SCI. USA, (199803), vol. 95, pages 3597 - 3602, XP002906679 DOI: http://dx.doi.org/10.1073/pnas.95.7.3597 | [Y] - KWON ET AL., "Functions of newly identified members of the tumor necrosis factor receptor/ligand superfamilies in lymphocytes", CURRENT OPINION IN IMMUNOLOGY, (1999), vol. 11, pages 340 - 345, XP004257544 DOI: http://dx.doi.org/10.1016/S0952-7915(99)80054-5 |